EyePoint Pharmaceuticals Inc (EYPT)
11.72
-0.34
(-2.82%)
USD |
NASDAQ |
Nov 04, 12:54
EyePoint Pharmaceuticals Gross Profit Margin (Quarterly): 85.22% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 85.22% |
| March 31, 2024 | 93.50% |
| December 31, 2023 | 92.89% |
| September 30, 2023 | 92.09% |
| June 30, 2023 | 80.32% |
| March 31, 2023 | 91.67% |
| December 31, 2022 | 67.63% |
| September 30, 2022 | 85.97% |
| June 30, 2022 | 85.01% |
| March 31, 2022 | 80.88% |
| December 31, 2021 | 73.73% |
| September 30, 2021 | 79.85% |
| June 30, 2021 | 78.60% |
| March 31, 2021 | 81.02% |
| December 31, 2020 | 65.49% |
| September 30, 2020 | 88.01% |
| June 30, 2020 | 87.82% |
| March 31, 2020 | 86.91% |
| December 31, 2019 | 84.66% |
| September 30, 2019 | 86.97% |
| June 30, 2019 | 90.21% |
| March 31, 2019 | 83.60% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 |
| Date | Value |
|---|---|
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | |
| March 31, 2014 | |
| December 31, 2013 | |
| September 30, 2013 | |
| June 30, 2013 | |
| March 31, 2013 | |
| December 31, 2012 | |
| September 30, 2012 | |
| June 30, 2012 | |
| March 31, 2012 | |
| December 31, 2011 |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
65.49%
Minimum
Dec 2020
93.50%
Maximum
Mar 2024
83.22%
Average
85.01%
Median
Jun 2022
Gross Profit Margin (Quarterly) Benchmarks
| Cassava Sciences Inc | -- |
| Adverum Biotechnologies Inc | -- |
| Regenxbio Inc | 52.55% |
| Editas Medicine Inc | -- |
| Apellis Pharmaceuticals Inc | 88.43% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -50.45% |
| Return on Assets | -32.29% |
| Return on Invested Capital | -50.45% |
| Profit Margin (Quarterly) | -325.3% |
| Operating Margin (Quarterly) | -364.5% |
| Return on Net Operating Assets | -327.8% |